This study is in progress, not accepting new patients
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Summary
- Eligibility
- for people ages 2-17 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Melvin Heyman
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Melvin Heyman
Professor, Pediatrics, School of Medicine. Authored (or co-authored) 334 research publications. Research interests: inflammatory bowel disease (ulcerative colitis · Crohn's disease) · Pediatric Nutrition · Pancreatitis in children (acute and chronic) · Mentoring and Career Development · Fellowship Training · Gastroesophageal Reflux Disease
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Takeda
- Links
- To obtain more information on the study, click on this link
- ID
- NCT03196427
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- About 59 people participating
- Last Updated